ArticleEuropean journal of clinical pharmacology2012
Comparative adherence to oxybutynin or tolterodine among older patients.
Article in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.Neurourology and urodynamics · 2022Article
- Observational
- Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization.Journal of the American Heart Association · 2018Article
- Efficacy of posterior tibial nerve stimulation (PTNS) on overactive bladder in older adults.European geriatric medicine · 2018Article
- Drugs for the overactive bladder: are there differences in persistence and compliance?Translational andrology and urology · 2017Article
- Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study.Drugs - real world outcomes · 2016Article
- Persistence and compliance with medication management in the treatment of overactive bladder.Investigative and clinical urology · 2016Review
- Overactive bladder: strategies to ensure treatment compliance and adherence.Clinical interventions in aging · 2016Review
- Extended-release nifedipine and the risk of intestinal obstruction: a population-based study.BMJ open · 2014Article
- β3-receptor agonists for overactive bladder--new frontier or more of the same?Current urology reports · 2013Review
- New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Therapeutics and clinical risk management · 2013Article
- Comparative adherence to oxybutynin or tolterodine among older patients.European journal of clinical pharmacology · 2012Article
- Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Antimuscarinic use and discontinuation in an older adult population.Archives of gerontology and geriatricsArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare persistence of oxybutynin or tolterodine therapy among older patients newly prescribed one of these drugs.
methodsWe conducted a retrospective cohort study of Ontarians aged 66 years and older who were newly prescribed either drug between January 1, 2000 and December 31, 2007. Persistence with treatment was defined on the basis of refills for the drug within a grace period equal to 50% of the prescription duration.
resultsWe identified 31,996 patients newly treated with oxybutynin and 24,855 newly treated with tolterodine. After 2 years of follow-up, persistence on oxybutynin (9.4%) was significantly lower than that on tolterodine (13.6%, p < 0.0001). The median time to discontinuation of oxybutynin and tolterodine was 68 and 128 days, respectively.
conclusionsOur findings suggest that the tolerability of these drugs differs substantially.
Indexed as
Identifiers
21710237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.